Treatment for Keratoconus

Phase-Based Progress Estimates
UPMC Eye Center, Pittsburgh, PA
Keratoconus+1 More
All Sexes
What conditions do you have?

Study Summary

This study is being conducted to evaluate the safety and effectiveness of using the PXL Platinum 330 system for performing corneal collagen cross-linking (CXL) for the treatment of corneal thinning disorders. The PXL Platinum 330 system is a combination product consisting of a UVA 365 nm wavelength light source (PXL Platinum 330 Illumination System) and riboflavin (Peschke-TE 0.25% ophthalmic solution or Peschke-L 0.23% ophthalmic solution) administered in conjunction with the UVA light as a photosensitizer.

Eligible Conditions

  • Corneal Thinning
  • Keratoconus

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 12 months

12 months
Efficacy measurements by best spectacle-corrected visual acuity
PXL-Platinum 330 system

Trial Safety

Trial Design

0 Treatment Group

300 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · Phase 1 & 2

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 months
Closest Location: UPMC Eye Center · Pittsburgh, PA
Photo of Pittsburgh  1Photo of Pittsburgh  2Photo of Pittsburgh  3
2010First Recorded Clinical Trial
4 TrialsResearching Keratoconus
16 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have keratoconus, post-surgical ectasia, or pellucid marginal degeneration.
You have a difference in keratometry of at least 1.
You have a corneal thickness of less than or equal to 485 microns.
You are at least 18 years old.
Presence of one or more findings associated with keratoconus or pellucid marginal degeneration, such as: a
The steepest keratometry (Kmax) value is 47.20 D or higher.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.